{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:14:33Z","timestamp":1786986873718,"version":"build-2736575974"},"reference-count":17,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.clinre.2024.102358","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T03:03:59Z","timestamp":1714100639000},"page":"102358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["PPAR agonists in PBC: Where do we go from here? Or how to choose between the new and the old"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6358-5283","authenticated-orcid":false,"given":"Atsushi","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Corpechot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinre.2024.102358_bib0001","article-title":"Efficacy and safety of elafibranor in primary biliary cholangitis","author":"Kowdley","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2024.102358_bib0002","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A phase 3 trial of seladelpar in primary biliary cholangitis","volume":"390","author":"Hirschfield","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2024.102358_bib0003","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2024.102358_bib0004","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2024.102358_bib0005","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1056\/NEJMe1804945","article-title":"Progress in primary biliary cholangitis","volume":"378","author":"Carey","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2024.102358_bib0006","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinre.2024.102358_bib0007","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2024.102358_bib0008","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1386-6346(99)00033-9","article-title":"Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis","volume":"16","author":"Iwasaki","year":"1999","journal-title":"Hepatology Research"},{"key":"10.1016\/j.clinre.2024.102358_bib0009","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jhep.2021.04.010","article-title":"Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis","volume":"75","author":"Tanaka","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2024.102358_bib0010","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","article-title":"Fibrates for Itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial","volume":"160","author":"de Vries","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2024.102358_bib0011","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/apt.16618","article-title":"Bezafibrate therapy in primary biliary cholangitis refractory to ursodeoxycholic acid: a longitudinal study of paired liver biopsies at 5 years of follow up","volume":"54","author":"Sorda","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinre.2024.102358_bib0012","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1002\/hep.31613","article-title":"Improved markers of cholestatic liver injury in patients with primary biliary cholangitis treated with obeticholic acid and bezafibrate","volume":"73","author":"Smets","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2024.102358_bib0013","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/apt.16336","article-title":"Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis","volume":"53","author":"Soret","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinre.2024.102358_bib0014","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000000864","article-title":"Primary biliary cholangitis drug evaluation and regulatory approval: where do we go from here?","author":"Jones","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2024.102358_bib0015","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJMe2312745","article-title":"Advancing second-line treatment for primary biliary cholangitis","volume":"390","author":"Assis","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2024.102358_bib0016","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1056\/NEJMe2313802","article-title":"PPAR agonists in primary biliary cholangitis","volume":"390","author":"Schnabl","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2024.102358_bib0017","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/hepr.13931","article-title":"Determinants of the effectiveness of bezafibrate combined with ursodeoxycholic acid in patients with primary biliary cholangitis","volume":"53","author":"Matsumoto","year":"2023","journal-title":"Hepatol Res"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740124000792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740124000792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T11:51:51Z","timestamp":1717329111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740124000792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2210740124000792"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2024.102358","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PPAR agonists in PBC: Where do we go from here? Or how to choose between the new and the old","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2024.102358","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102358"}}